Current and Prospective Therapies for Double-Hit Lymphoma
In a review, researchers discussed the value of combining immunotherapy, targeted therapy, and chemotherapy to improve treatment for double hit lymphoma.
Lymphoma
LYMPHOMA ADVISOR
FEATURED CONTENT
-
-
The Evolution of Frontline Hodgkin Lymphoma Treatment
With numerous options, there is growing debate over the frontline treatment of Hodgkin lymphoma. -
Pembrolizumab Shows Promise in Post-ASCT Hodgkin Lymphoma
Pembrolizumab improved PFS in this high-risk patient population, but a randomized controlled trial is warranted. -
Susceptibility to Radiation-Induced Breast Cancer Following Treatment for Hodgkin Lymphoma
Genetic variants associated with radiation-induced breast cancer include MYC-adjacent oncogene PVT1. -
Understanding the Limitations of CAR-T Cell Therapies
CAR-T’s inability to induce durable remissions in many patients is a barrier to the success of these adoptive cell therapies—but solutions are under way.
VIDEO SERIES
LYMPHOMA NEWS
Surveillance Imaging Not Linked to Better Outcomes in Follicular Lymphoma, Further Evidence Shows
The Utility of Endoscopic Techniques in the Diagnosis of Gastric Lymphoma
HIV-Induced Expression of PD-L1 on Regulatory B Cells May Promote AIDS-Related NHL
Efficacy of 19-28z CAR-T in DLBCL Unclear: Phase 1 Study Readout
Increased Risk for Second Malignancy After Multiple Lines of Treatment in Follicular Lymphoma
Want to read more?
Please login or register first to view this content.
Next post in Lymphoma
